相关实验视频
Updated: Jul 12, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
关于BCL-2抑制剂的当前进展和未来战略:对抗癌症的强大武器
Jiaxuan Xu1, Xiaoqing Dong1, David C S Huang2,3
1Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing 210008, China.
像venetoclax这样的B细胞淋巴瘤-2 (BCL-2) 抑制剂在通过诱导亡来治疗癌症方面表现有前途. 然而,患者的反应和耐药性变化需要进一步研究生物标志物和固体瘤应用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 向B细胞淋巴瘤-2 (BCL-2) 蛋白质对于克服癌细胞亡回避至关重要.
- 抗BCL-2抑制剂,特别是venetoclax,通过诱导瘤细胞亡来有效治疗血液性恶性瘤.
- 维尼托克拉克斯被纳入慢性淋巴细胞白血病和急性髓性白血病的治疗方案中,并且在多发性骨髓瘤和淋巴瘤中显示出有效性.
研究的目的:
- 审查BCL-2抑制剂的治疗前景,重点关注venetoclax.
- 讨论现实世界患者群体中可变治疗结果和耐药性的挑战.
- 探索BCL-2抑制剂,包括venetoclax在固体瘤治疗中的潜力.
主要方法:
- 关于BCL-2抑制剂的临床前和临床研究的文献综述.
- 分析venetoclax在各种血液性恶性瘤和固体瘤中的疗效.
- 关于预测对BCL-2抑制治疗反应的生物标志物的研究摘要.
主要成果:
- 威尼托克拉克斯在血液性恶性瘤中表现出显著的抗瘤活性,影响治疗策略.
- 个体患者对venetoclax的反应各不相同,药物敏感性问题导致复发.
- 临床前模型显示,BCL-2抑制剂在固体瘤的组合疗法中取得了有希望的结果.
结论:
- 需要新的生物标志物来预测BCL-2抑制疗法的有效性,并个性化治疗.
- 需要在固体瘤中对venetoclax进行进一步的临床研究.
- 涉及BCL-2抑制剂的组合疗法显示出更广泛的癌症治疗应用的潜力.
更多相关视频
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Inhibition of Cdk Activity
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...